关键词：精神分裂症；慢性脑部疾病；扰乱大脑；药物治疗；心理帮助
摘 要：Schizophrenia is a chronic brain disorder that severely affects the quality of life of a patient by disturbing the normal functioning of the brain. Psychotic symptoms and a diminished range of expression of emotions are the characteristics of schizophrenia. The exact etiology of schizophrenia is still not known. In men, it appears in the late teens or early 20s, and in women in the late 20s or early 30s. However, most of the symptoms of this disorder can be managed with medication and psychological help.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Schizophrenia Therapeutics Market in US

06.3.1 Market Size and Forecast

06.4 Five Forces Analysis

07. Pipeline Snapshot

08. Rate of Incidence and Prevalence

08.1.1 US

09. Types of Schizophrenia

10. Phases of Schizophrenia

10. Market Segmentation by Drug Class

10.1 Global Schizophrenia Therapeutics Market

Segmentation by Drug Class

11. Geographical Segmentation

11.1 Global Schizophrenia Therapeutics Market by

Geographical Segmentation 2013

11.2 Schizophrenia Therapeutics Market in Americas

11.2.1 Market Size and Forecast

11.3 Schizophrenia Therapeutics Market in APAC

Region

11.3.1 Market Size and Forecast

11.4 Schizophrenia Therapeutics Market in EMEA

Region

11.4.1 Market Size and Forecast

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

19.1 Competitive Scenario

19.1.1 Key News

19.1.2 Mergers and Acquisitions

19.2 Market Share Analysis 2013

19.3 Other Prominent Vendors

20. Key Vendor Analysis

20.1 AstraZeneca

20.1.1 Key Facts

20.1.2 Business Description

20.1.3 Business Segmentation

20.1.4 Business Strategy

20.1.5 Revenue by Business Segmentation

20.1.6 Revenue Comparison 2011-2013

20.1.7 Sales Revenue by Geographical Segmentation

20.1.8 Key Developments

20.1.9 SWOT Analysis

20.2 Bristol-Myers Squibb

20.2.1 Key Facts

20.2.2 Business Overview

20.2.3 Key Product Offerings

20.2.4 Revenue by Geographical Segmentation

20.2.5 Business Strategy

20.2.6 Key Information

20.2.7 SWOT Analysis

20.3 Eli Lilly

20.3.1 Key Facts

20.3.2 Business Overview

20.3.3 Business Segmentation by Revenue

20.3.4 Revenue by Geographical Segmentation

20.3.5 Business Strategy

20.3.6 Key Information

20.3.7 SWOT Analysis

20.4 F. Hoffmann-La Roche

20.4.1 Key Facts

20.4.2 Business Overview

20.4.3 Business Segmentation

20.4.4 Business Segmentation by Revenue 2012 and 2013

20.4.5 Revenue by Geographical Segmentation

20.4.6 Business Strategy

20.4.7 Key Information

20.4.8 SWOT Analysis

20.5 Johnson & Johnson

20.5.1 Key Facts

20.5.2 Business Overview

20.5.3 Business Segmentation by Revenue 2013

20.5.4 Business Segmentation by Revenue 2012 and 2013

20.5.5 Geographical Segmentation by Revenue 2013

20.5.6 Business Strategy

20.5.7 Recent Developments

20.5.8 SWOT Analysis

20.6 Lundbeck

20.6.1 Key Facts

20.6.2 Business Overview

20.6.3 Product Segmentation by Revenue 2013

20.6.4 Product Segmentation by Revenue 2012 and 2013

20.6.5 Geographical Segmentation by Revenue

20.6.6 Business Strategy

20.6.7 Recent Developments

20.6.8 SWOT Analysis

20.7 Otsuka Pharmaceuticals

20.7.1 Key Facts

20.7.2 Business Overview

20.7.3 Business Segmentation by Revenue 2014

20.7.4 Business Segmentation by Revenue 2013 and 2014

20.7.5 Geographical Segmentation by Revenue 2014

20.7.6 Business Strategy

20.7.7 Recent Developments

20.7.8 SWOT Analysis

20.9 Pfizer

20.9.1 Key Facts

20.9.2 Business Overview

20.9.3 Business Segmentation by Revenue 2013

20.9.4 Business Segmentation by Revenue 2012 and 2013

20.9.5 Geographical Segmentation by Revenue

20.9.6 Business Strategy

20.9.7 Key Developments

20.9.8 SWOT Analysis

20.10 Sumitomo Dainippon Pharma

20.10.1 Key Facts

20.10.2 Business Overview

20.10.3 Product Segmentation

20.10.4 Product Segmentation by Revenue 2013 and 2014

20.10.5 Business Strategy

20.10.6 Recent Developments

20.10.7 SWOT Analysis

21. Other Reports in this Series